BRIEF-Nuvalent Announces Key Program And Business Updates, Strengthening Foundation For Global Leadership In Ros1- And Alk-Positive Nsclc

Nuvalent, Inc. Class A

Nuvalent, Inc. Class A

NUVL

0.00

- Nuvalent, Inc NUVL.O:

  • NUVALENT ANNOUNCES KEY PROGRAM AND BUSINESS UPDATES, STRENGTHENING FOUNDATION FOR GLOBAL LEADERSHIP IN ROS1- AND ALK-POSITIVE NSCLC

  • NUVALENT, INC - FDA ACCEPTS NDA FOR NELADALKIB WITH PRIORITY REVIEW; PDUFA DATE NOVEMBER 27, 2026

Source text: ID:nPn48WYMwa

Further company coverage: NUVL.O